Healthcare · Reviewed June 17, 2026

Exscientia

AI-driven pharmatech company specializing in drug discovery and development, pioneering AI-designed molecules for clinical trials.

Category
Pricing
Paid
Rating
4.84/ 5 · 163 reviews
Last reviewed
June 17, 2026
Channels
Exscientia AI Drug Discovery Platform

Acquired Exscientia

Acquired · November 2024

Acquired by Recursion in Nov 2024 (~$650M all-stock deal). Combined company creates vertically integrated AI drug discovery platform.

Acquired by Recursion.

01

Overview

Exscientia: Leading the AI Drug Discovery Revolution

Exscientia, a prominent AI-driven pharmatech company, is at the forefront of revolutionizing drug discovery. The company's innovative approach combines the power of AI with human creativity to develop safer and more sophisticated drugs. Exscientia's AI platform, known for its efficiency and quality, has made significant strides in the pharmaceutical industry. It is recognized for creating the first AI-designed molecules to enter clinical trials, demonstrating groundbreaking clinical impact. The platform's patient-first AI approach has shown improved treatment outcomes in interventional studies. Exscientia's mission is to harness AI to precision engineer future drugs, revolutionizing the drug discovery process.

Key Features:

  • AI-Designed Drug Molecules: Pioneering the development of AI-designed drugs for clinical trials.
  • Patient-First AI Platform: Focuses on improving treatment outcomes with AI-driven insights.
  • Efficient Drug Discovery: Reduces the time and resources needed for drug development.
  • Quality Drug Design: Integrates key criteria from the outset for successful drug development.
  • Innovative AI Systems: Employs advanced AI for faster and more efficient learning in drug discovery.

Ideal Use Case:

Exscientia is ideal for biopharmaceutical companies, researchers, and healthcare professionals involved in drug discovery and development. It's particularly beneficial for those seeking to leverage AI for faster and more efficient discovery of treatments for various diseases.

Why use Exscientia:

  • Accelerated Drug Discovery: Speeds up the process of finding new treatments.
  • Data-Driven Insights: Utilizes AI for informed drug development decisions.
  • Innovative AI Technology: Employs cutting-edge AI for groundbreaking scientific research.
  • Improved Clinical Success: Aims to enhance the probability of clinical success of drugs.
  • Patient-Centric Approach: Focuses on developing drugs with a higher likelihood of benefiting patients.

tl;dr:

Exscientia is revolutionizing the field of drug discovery with its AI-driven approach, offering innovative solutions to accelerate the development of new treatments. With its advanced platform and strategic focus on patient outcomes, Exscientia is making significant strides in transforming the biopharma industry.

FAQ

Q: What is Exscientia? A: AI-driven pharmatech company specializing in drug discovery and development, pioneering AI-designed molecules for clinical trials.

Q: How much does Exscientia cost? A: Pricing varies by plan. Visit the Exscientia pricing page for current tiers and details.

Q: Who is Exscientia's ideal user? A: clinicians and healthcare ops teams use Exscientia in their day-to-day workflow.

Q: What competes with Exscientia? A: Top alternatives to Exscientia include Abridge, Flatiron Health, and Innovaccer. See our directory for in-depth comparisons.

Related

Looking for more options? Browse the Healthcare directory or read our best AI healthcare tools listicle. Exscientia is also tracked on Crunchbase.

02

Why Use Exscientia

Rating
4.84
Across 163 verified reviews
Saved
248
By ToolDirectory readers
Pricing
Inquire
Paid · publisher-listed
Listed
Since 2024
Continuously re-reviewed by editors
Category
Healthcare
Primary listing
Verified by editors during the most recent review · ToolDirectory.AI
Exscientia AI Drug Discovery
03

User Reviews

4.84
Out of 5 · 163 ratings
5
147
4
10
3
3
2
2
1
1

Sign up for our newsletter

Receive weekly updates so you can stay up-to-date with the world of AI